Key Highlights

  • Ensysce Biosciences amended its Series C Non-Voting Convertible Preferred Stock to delete Section 6.5.3 of its certificate of designation.
  • The deleted provision let holders Demand cash at Fair Value if the company failed to deliver common stock.
  • The amendment became effective on filing on September 25, 2026, so no further corporate step is needed.
  • Conversion of the Series C shares remains subject to stockholder approval under Nasdaq rules, according to the filing.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) has amended the terms of its Series C Non-Voting Convertible Preferred Stock to delete a provision that let holders demand cash for their shares. The amendment, which the company says became effective on filing on September 25, 2026, removes Section 6.5.3 of the certificate of designation.

The change was reported in a Form 8-K filed September 29, 2026 under Item 5.03, the item for amendments to a company's articles of incorporation or bylaws. Ensysce trades on Nasdaq under the symbol ENSC.

What Was Removed

According to the filing, Section 6.5.3 had provided that the Preferred Shares were redeemable for cash at the option of the holder at any time following stockholder approval, at a price per share equal to the then-current fair value, in a situation where the company failed to deliver common stock. The Certificate of Amendment deletes that section. Without it, the Series C terms no longer give holders a cash-redemption right triggered by a Failure to Deliver common shares.

Series C Background

The Series C Non-Voting Convertible Preferred Stock has a Par Value of $0.0001 per share. The report states that the Certificate of Designation for the series was filed on August 5, 2026, with a certificate of correction on August 6, 2026. The shares are convertible into common stock, and the filing says conversion is subject to the Nasdaq stock market rules, which require stockholder approval before conversion.

Preferred stock terms are set in a certificate of designation filed with the company's state of incorporation, Delaware. A company can amend those terms, and the 8-K describes the amendment as effective upon filing. Item 5.03 reports are usually brief, because the amended document itself is attached as an exhibit and controls the exact wording.

Ensysce's Series C Conversion and Nasdaq Approval Question

The amendment took effect on September 25, 2026, so no further corporate step is needed for it to operate. The related question is stockholder approval of conversion under Nasdaq rules, which the filing says is required before the Series C shares convert. The current filing sets no dates.